Peptide vaccines in cancer — old concept revisited

Takumi Kumai, Hiroya Kobayashi, Yasuaki Harabuchi, Esteban Celis

Research output: Contribution to journalReview articlepeer-review

43 Scopus citations

Abstract

Synthetic peptide vaccines aim to elicit and expand tumor-specific T cells capable of controlling or eradicating the tumor. Despite the high expectations based on preclinical studies, the results of clinical trials using peptide vaccines have been disappointing. Thus, many researchers in the field have considered peptide vaccines as outdated and no longer viable for cancer therapy. However, recent progress in understanding the critical roles of immune adjuvants, modes of vaccine administration and T cell dynamics has lead to a rebirth of this approach and reconsidering the use of peptide vaccines for treating malignant disorders.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalCurrent Opinion in Immunology
Volume45
DOIs
StatePublished - Apr 1 2017

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Peptide vaccines in cancer — old concept revisited'. Together they form a unique fingerprint.

Cite this